BR9916906A - Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto - Google Patents

Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto

Info

Publication number: BR9916906A
Authority: BR; Brazil
Prior art keywords: compound; alkyl; treatment; prophylaxis; zero
Prior art date: 1999-01-15

Application number

BR9916906-1A

Other languages

English (en)

Portuguese (pt)

Inventor

James Loch Iii

George Mullen

Eifion Phillips

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-15

Filing date

1999-12-23

Publication date

2001-10-30

1999-12-23 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-10-30 Publication of BR9916906A publication Critical patent/BR9916906A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

BR9916906-1A 1999-01-15 1999-12-23 Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto BR9916906A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9900100A SE9900100D0 (sv)	1999-01-15	1999-01-15	New compounds
PCT/SE1999/002478 WO2000042044A1 (fr)	1999-01-15	1999-12-23	Nouvelles aralkylamines de spirofuropyridines utiles en therapie

Publications (1)

Publication Number	Publication Date
BR9916906A true BR9916906A (pt)	2001-10-30

Family

ID=20414101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9916906-1A BR9916906A (pt)	1999-01-15	1999-12-23	Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto

Country Status (34)

Country	Link
US (2)	US6995167B2 (fr)
EP (1)	EP1147114B1 (fr)
JP (1)	JP2002534525A (fr)
KR (1)	KR100660496B1 (fr)
CN (1)	CN1132837C (fr)
AR (1)	AR022283A1 (fr)
AT (1)	ATE240960T1 (fr)
AU (1)	AU775433B2 (fr)
BR (1)	BR9916906A (fr)
CA (1)	CA2359990A1 (fr)
CZ (1)	CZ20012554A3 (fr)
DE (1)	DE69908185T2 (fr)
DK (1)	DK1147114T3 (fr)
EE (1)	EE04528B1 (fr)
ES (1)	ES2200590T3 (fr)
HK (1)	HK1040517B (fr)
HU (1)	HUP0200513A3 (fr)
ID (1)	ID30034A (fr)
IL (1)	IL144266A0 (fr)
IS (1)	IS6000A (fr)
MY (1)	MY118109A (fr)
NO (1)	NO20013478L (fr)
NZ (1)	NZ512733A (fr)
PT (1)	PT1147114E (fr)
RU (1)	RU2233282C2 (fr)
SA (1)	SA00200987B1 (fr)
SE (1)	SE9900100D0 (fr)
SI (1)	SI1147114T1 (fr)
SK (1)	SK9932001A3 (fr)
TR (1)	TR200102042T2 (fr)
TW (2)	TW200413387A (fr)
UA (1)	UA71598C2 (fr)
WO (1)	WO2000042044A1 (fr)
ZA (1)	ZA200105527B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
FR2790474B1 (fr) *	1999-03-05	2001-04-06	Synthelabo	Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
PT1397366E (pt) *	2001-06-01	2007-04-30	Astrazeneca Ab	Novo ligando para os receptores nicotínicos da acetilcolina úteis em terapia
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
DK1432707T3 (da) *	2001-10-02	2012-06-11	Pharmacia & Upjohn Co Llc	Azabicyklisk-substituerede kondenserede heteroarylforbindelser til behandling af sygdomme
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
NZ561993A (en) *	2002-04-18	2008-09-26	Astrazeneca Ab	Spiroazabicyclic heterocyclic amines as potent ligands for nicotinic acetylcholine receptors
BR0309342A (pt) *	2002-04-18	2005-02-15	Astrazeneca Ab	Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CN1325500C (zh) *	2002-04-18	2007-07-11	阿斯特拉曾尼卡有限公司	呋喃基化合物
CA2495248A1 (fr)	2002-08-30	2004-03-11	Memory Pharmaceuticals Corporation	Derives d'anabaseine utiles pour le traitement de maladies neurodegeneratives
SE0202598D0 (sv) *	2002-09-02	2002-09-02	Astrazeneca Ab	Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en)	2002-09-04	2002-10-09	Novartis Ag	Organic Compound
EE05516B1 (et)	2002-09-25	2012-02-15	Memory@Pharmaceuticals@Corporation	Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
US7238715B2 (en) *	2002-12-06	2007-07-03	The Feinstein Institute For Medical Research	Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004052365A2 (fr) *	2002-12-06	2004-06-24	North Shore-Long Island Jewish Research Institute	Inhibition d'inflammation au moyen d'agonistes cholinergiques se liant au recepteur alpha 7
JP4598674B2 (ja) *	2003-01-08	2010-12-15	田辺三菱製薬株式会社	統合失調症治療剤
WO2005000250A2 (fr) *	2003-06-24	2005-01-06	Johns Hopkins University	Agents d'imagerie et procedes d'imagerie du recepteur cholinergique nicotinique alpha 7
CA2543436A1 (fr)	2003-10-21	2005-05-12	Astrazeneca Ab	Derives aryliques de spirofuropyridine
US7045530B2 (en)	2003-12-22	2006-05-16	Abbott Laboratories	Spirocyclic quinuclidinic ether derivatives
CA2560741C (fr)	2004-03-25	2013-08-06	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
AR049401A1 (es)	2004-06-18	2006-07-26	Novartis Ag	Aza-biciclononanos
GB0415746D0 (en)	2004-07-14	2004-08-18	Novartis Ag	Organic compounds
AR053710A1 (es) *	2005-04-11	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
GB0521508D0 (en)	2005-10-21	2005-11-30	Novartis Ag	Organic compounds
US8316104B2 (en)	2005-11-15	2012-11-20	California Institute Of Technology	Method and apparatus for collaborative system
GB0525672D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
GB0525673D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
RU2448111C2 (ru) *	2006-08-21	2012-04-20	Дженентек, Инк.	Соединения азабензофуранила и способ их применения
TW200901974A (en)	2007-01-16	2009-01-16	Wyeth Corp	Compounds, compositions, and methods of making and using them
SA08290475B1 (ar) *	2007-08-02	2013-06-22	Targacept Inc	(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2728675A1 (fr)	2008-06-20	2009-12-23	Astrazeneca Ab	Derives de dibenzothiazepine et leur utilisation
CN105218565A (zh)	2008-10-17	2016-01-06	泽农医药公司	螺羟吲哚化合物及其作为治疗剂的用途
PE20110711A1 (es)	2008-11-19	2011-10-11	Envivo Pharmaceuticals Inc	Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
TW201031664A (en)	2009-01-26	2010-09-01	Targacept Inc	Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2429518A1 (fr) *	2009-05-11	2012-03-21	Envivo Pharmaceuticals, Inc.	Traitement de troubles cognitifs avec certains récepteurs nicotiniques de type alpha-7 à en combinaison avec des inhibiteurs de l'acétylcholinestérase
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8445696B2 (en)	2009-10-14	2013-05-21	Xenon Pharmaceuticals Inc.	Synthetic methods for spiro-oxindole compounds
CA2788440A1 (fr)	2010-02-26	2011-09-01	Xenon Pharmaceuticals Inc.	Compositions pharmaceutiques de compose spiro-oxindole pour administration topique et leur utilisation en tant qu'agents therapeutiques.
MX2012013345A (es)	2010-05-17	2013-02-11	Envivo Pharmaceuticals Inc	Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
GB201111705D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Compounds and their use
GB201111704D0 (en)	2011-07-07	2011-08-24	Takeda Pharmaceutical	Novel compounds
JO3115B1 (ar)	2011-08-22	2017-09-20	Takeda Pharmaceuticals Co	مركبات بيريدازينون واستخدامها كمثبطات daao
HK1205114A1 (en)	2012-04-12	2015-12-11	Xenon Pharmaceuticals Inc.	Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
RU2635522C2 (ru)	2012-05-08	2017-11-13	Форум Фармасьютикалз, Инк.	Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en)	2012-05-30	2012-07-11	Takeda Pharmaceutical	Therapeutic compounds
CN105189482A (zh)	2013-02-07	2015-12-23	武田药品工业株式会社	作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
AU2014282977B2 (en)	2013-06-21	2018-06-14	Takeda Pharmaceutical Company Limited	1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en)	2013-08-08	2013-09-25	Takeda Pharmaceutical	Therapeutic Compounds
GB201318222D0 (en)	2013-10-15	2013-11-27	Takeda Pharmaceutical	Novel compounds
GB201320905D0 (en)	2013-11-27	2014-01-08	Takeda Pharmaceutical	Therapeutic compounds
TW201613864A (en)	2014-02-20	2016-04-16	Takeda Pharmaceutical	Novel compounds
AR103636A1 (es)	2015-02-05	2017-05-24	Teva Pharmaceuticals Int Gmbh	Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (fr)	2016-06-16	2017-12-21	Teva Pharmaceuticals International Gmbh	Synthèse asymétrique de funapide
GB201616839D0 (en)	2016-10-04	2016-11-16	Takeda Pharmaceutical Company Limited	Therapeutic compounds
GB201619514D0 (en)	2016-11-18	2017-01-04	Takeda Pharmaceuticals Co	Novel compounds
JP2021138648A (ja)	2020-03-04	2021-09-16	武田薬品工業株式会社	経口固形製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE122353T1 (de) *	1987-10-05	1995-05-15	Yamanouchi Pharma Co Ltd	Heterozyklische spiroverbindungen und ihre herstellung.
JPH0195922A (ja)	1987-10-08	1989-04-14	Mazda Motor Corp	車両のサスペンション制御装置
SU1540240A1 (ru) *	1988-05-16	1995-09-10	Институт Тонкой Органической Химии Им.А.Л.Мнджояна	5-ЗАМЕЩЕННЫЕ 1-АМИНО -8,9-ДИГИДРО -8,8-ДИМЕТИЛ-3, 6Н- ПИРАЗОЛО [3,4-B] ПИРАНО[[4′,3′-d]] ПИРИДИНА ИЛИ ИХ ГИДРОХЛОРИДЫ, ОБЛАДАЮЩИЕ ПРОТИВОСУДОРОЖНОЙ АКТИВНОСТЬЮ
HUT77352A (hu) *	1994-08-24	1998-03-30	Astra Aktiebolag	Spiro[aza-bicikloalkán-oxazolidin]-2'-on-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ATE200084T1 (de) *	1995-07-28	2001-04-15	Abbott Lab	Furo-, thieno- und pyrrolopyridine und verwandte pyrinidin-, pyridazin- und triazinverbindungen verwendbar zur kontrolle von chemische synaptische übertragung
US6156783A (en)	1996-04-30	2000-12-05	Smithkline Beecham P.L.C.	Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
AR013184A1 (es) *	1997-07-18	2000-12-13	Astrazeneca Ab	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds

1999
- 1999-01-15 SE SE9900100A patent/SE9900100D0/xx unknown
- 1999-12-23 NZ NZ512733A patent/NZ512733A/en unknown
- 1999-12-23 CZ CZ20012554A patent/CZ20012554A3/cs unknown
- 1999-12-23 US US09/529,654 patent/US6995167B2/en not_active Expired - Fee Related
- 1999-12-23 CN CN998164224A patent/CN1132837C/zh not_active Expired - Fee Related
- 1999-12-23 CA CA002359990A patent/CA2359990A1/fr not_active Abandoned
- 1999-12-23 WO PCT/SE1999/002478 patent/WO2000042044A1/fr not_active Ceased
- 1999-12-23 ID IDW00200101529A patent/ID30034A/id unknown
- 1999-12-23 JP JP2000593611A patent/JP2002534525A/ja active Pending
- 1999-12-23 BR BR9916906-1A patent/BR9916906A/pt not_active Application Discontinuation
- 1999-12-23 DE DE69908185T patent/DE69908185T2/de not_active Expired - Fee Related
- 1999-12-23 RU RU2001122812/04A patent/RU2233282C2/ru not_active IP Right Cessation
- 1999-12-23 HU HU0200513A patent/HUP0200513A3/hu unknown
- 1999-12-23 HK HK02102161.7A patent/HK1040517B/en not_active IP Right Cessation
- 1999-12-23 SI SI9930375T patent/SI1147114T1/xx unknown
- 1999-12-23 AT AT99967044T patent/ATE240960T1/de not_active IP Right Cessation
- 1999-12-23 ES ES99967044T patent/ES2200590T3/es not_active Expired - Lifetime
- 1999-12-23 DK DK99967044T patent/DK1147114T3/da active
- 1999-12-23 UA UA2001085777A patent/UA71598C2/uk unknown
- 1999-12-23 EE EEP200100370A patent/EE04528B1/xx not_active IP Right Cessation
- 1999-12-23 IL IL14426699A patent/IL144266A0/xx unknown
- 1999-12-23 SK SK993-2001A patent/SK9932001A3/sk unknown
- 1999-12-23 EP EP99967044A patent/EP1147114B1/fr not_active Expired - Lifetime
- 1999-12-23 TR TR2001/02042T patent/TR200102042T2/xx unknown
- 1999-12-23 KR KR1020017008939A patent/KR100660496B1/ko not_active Expired - Fee Related
- 1999-12-23 PT PT99967044T patent/PT1147114E/pt unknown
- 1999-12-23 AU AU23343/00A patent/AU775433B2/en not_active Ceased
2000
- 2000-01-13 MY MYPI20000100A patent/MY118109A/en unknown
- 2000-01-13 AR ARP000100156A patent/AR022283A1/es not_active Application Discontinuation
- 2000-01-21 TW TW093106537A patent/TW200413387A/zh unknown
- 2000-01-21 TW TW089100989A patent/TWI227237B/zh not_active IP Right Cessation
- 2000-02-21 SA SA00200987A patent/SA00200987B1/ar unknown
2001
- 2001-07-04 ZA ZA200105527A patent/ZA200105527B/en unknown
- 2001-07-12 IS IS6000A patent/IS6000A/is unknown
- 2001-07-13 NO NO20013478A patent/NO20013478L/no not_active Application Discontinuation
2005
- 2005-07-14 US US11/181,098 patent/US7196096B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK1147114T3 (da)	2003-09-15
CA2359990A1 (fr)	2000-07-20
SI1147114T1 (en)	2003-12-31
NO20013478L (no)	2001-09-14
US20030149065A1 (en)	2003-08-07
HUP0200513A2 (en)	2002-06-29
EP1147114A1 (fr)	2001-10-24
UA71598C2 (en)	2004-12-15
AR022283A1 (es)	2002-09-04
US6995167B2 (en)	2006-02-07
KR20010086167A (ko)	2001-09-08
PT1147114E (pt)	2003-10-31
CN1132837C (zh)	2003-12-31
TW200413387A (en)	2004-08-01
KR100660496B1 (ko)	2006-12-22
CN1337964A (zh)	2002-02-27
US7196096B2 (en)	2007-03-27
SA00200987B1 (ar)	2006-11-07
JP2002534525A (ja)	2002-10-15
IL144266A0 (en)	2002-05-23
SK9932001A3 (en)	2002-04-04
AU2334300A (en)	2000-08-01
EP1147114B1 (fr)	2003-05-21
NZ512733A (en)	2003-08-29
TWI227237B (en)	2005-02-01
DE69908185T2 (de)	2004-06-03
HK1040517B (en)	2003-09-05
MY118109A (en)	2004-08-30
DE69908185D1 (de)	2003-06-26
CZ20012554A3 (cs)	2002-01-16
IS6000A (is)	2001-07-12
NO20013478D0 (no)	2001-07-13
ZA200105527B (en)	2002-10-04
EE200100370A (et)	2002-10-15
HUP0200513A3 (en)	2004-07-28
SE9900100D0 (sv)	1999-01-15
TR200102042T2 (tr)	2002-05-21
RU2233282C2 (ru)	2004-07-27
WO2000042044A1 (fr)	2000-07-20
EE04528B1 (et)	2005-08-15
US20050250802A1 (en)	2005-11-10
ES2200590T3 (es)	2004-03-01
ATE240960T1 (de)	2003-06-15
HK1040517A1 (en)	2002-06-14
ID30034A (id)	2001-11-01
AU775433B2 (en)	2004-07-29

Publication	Publication Date	Title
BR9916906A (pt)	2001-10-30	Composto, composição farmacêutica, uso de umcomposto, métodos de tratamento ou profilaxiade, distúrbios psicóticos ou distúrbios deenfraquecimento intelectual, e de tratamento ouprofilaxia de doenças ou condições humanas emque a ativação do receptor alfa-7 nicotìnico ébenéfica, e, processo para preparar um composto
BR9810924A (pt)	2000-08-15	Composto heterocìclico espiroazabicìclico, composição farmacêutica, uso de um composto, e, processos de tratamento ou profilaxia de doenças humanas ou condições em que a ativação do receptor nicotìnico alfa7 seja benéfica, de distúrbios psicóticos ou distúrbios do enfraquecimento intelectual e do desequilìbrio do ritmo circadiano normal devido a viagens subsÈnicas ou supersÈnicas, da cessação de fumar, do vìcio da nicotina, da dor e da colite ulcerativa e de preparação de um composto
PT1235826E (pt)	2004-01-30	Acrilamidas de quinuclidina
BR0015624A (pt)	2002-07-30	Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0015193A (pt)	2002-06-18	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
NZ336302A (en)	2000-08-25	Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
BRPI0110955B8 (pt)	2021-05-25	derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.
HUP0103404A2 (hu)	2002-05-29	Oxazolidinonszármazékok, eljárás előállításukra, és az azokat tartalmazó gyógyászati készítmények
DE60224172D1 (de)	2008-01-31	Formanilid-derivative als beta2-adrenorezeptor-agonisten
BR0317645A (pt)	2005-12-06	Composto ou um sal deste, composição farmacêutica, uso de um composto, e, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deterioração cognitiva em um mamìfero
HUP9900607A2 (hu)	1999-06-28	Pirido[2,3-d]-pirimidin-származékok és a vegyületeket tartalmazó gyógyászati készítmények
BRPI0417948A (pt)	2007-04-17	derivados de quinuclidina substituìda por bicicloheterociclo fundido
AR024145A1 (es)	2002-09-04	Derivados de 5-fenil-pirimidina
HUP0103063A2 (hu)	2003-02-28	Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
BR0209930A (pt)	2004-03-30	Composto, composição farmacêutica, método para tratar doenças proliferativas, e, uso de um composto
NO914960L (no)	1991-12-16	Medikamenter for canserterapi med antihistaminegenskaper
HUP0103096A2 (hu)	2002-05-29	2-Fenil-1-[4-(2-amino-etoxi)-benzil]-indol-származékok és ösztrogének kombinációját tartalmazó gyógyszerkészítmények
BRPI0408605A (pt)	2006-03-07	derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos
BR9807950A (pt)	2000-03-08	Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
RU2008110917A (ru)	2009-10-10	ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
BR0015195A (pt)	2002-06-18	Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma condição associada com a transmissão reduzida de nicotina para o tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para o tratamento ou profilaxia de doenças ou condições humanas
BR0211171A (pt)	2004-08-10	Compostos quìmicos
DK43683A (da)	1983-08-05	Aromatiske forbindelser med antihistamin-aktivitet, fremgangsmaade til deres fremstilling samt deres anvendelse
BR0211938A (pt)	2004-09-21	Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do dito composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo, e, método para tratar os distúrbios de fertilidade em pacientes em necessidade do mesmo
BR9806263A (pt)	2000-04-04	Derivados de 1,2,3,4-tetrahidro-benzofuro[3,2-c]piridina

Legal Events

Date	Code	Title	Description
2008-12-30	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2009-05-19	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.
2009-09-29	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.